Compare Inovio Pharmaceuticals Inc (INO) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Meta Platforms Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Meta Platforms Inc trades at $647.7 (market cap $1.64T). The key difference: Meta Platforms Inc is far larger — about 18371.2× Inovio Pharmaceuticals Inc's market cap, and Meta Platforms Inc pays a 0.33% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | META | |
|---|---|---|
Market Cap | $89.27M | $1.64T |
Sector | Health | Media |
52-Week High | $2.87 | $790.00 |
52-Week Low | $1.05 | $525.72 |
Enterprise Value | $60.28M | $1.65T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
META stock trades at $646.01, down 2.79% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $10.44 surpassing expectations of $6.70. Revenue grew to $201.0B in 2025, though net income dipped to $60.5B. Analyst sentiment remains overwhelmingly positive, with a consensus price target of $807.17. Recent news highlights the launch of Muse Spark AI and a legal ruling in Massachusetts regarding youth addiction claims.
The outlook for META is favorable, driven by AI innovation and robust financials, but risks include regulatory lawsuits and high capital expenditures. With 79% of analysts rating it a buy and a price target implying 25% upside, the stock presents a growth opportunity, though investors should weigh legal and competitive pressures against its strong market position and profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
